BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Apr 20, 2010
 |  BC Extra  |  Clinical News

Benlysta misses secondary lupus endpoints

Human Genome Sciences Inc. (NASDAQ:HGSI) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported additional data from the Phase III BLISS-76 trial of Benlysta belimumab to treat systemic lupus erythematosus (SLE). Both doses of Benlysta plus standard...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >